Published in Blood on March 15, 2007
Autophagy fights disease through cellular self-digestion. Nature (2008) 33.83
Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet (2009) 14.06
Role of autophagy in cancer. Nat Rev Cancer (2007) 10.88
Eaten alive: a history of macroautophagy. Nat Cell Biol (2010) 8.83
Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol (2008) 6.78
Pancreatic cancers require autophagy for tumor growth. Genes Dev (2011) 6.17
Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer (2012) 6.14
The double-edged sword of autophagy modulation in cancer. Clin Cancer Res (2009) 5.46
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther (2011) 4.39
The dynamic nature of autophagy in cancer. Genes Dev (2011) 3.57
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest (2009) 3.55
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal (2010) 3.35
Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest (2008) 2.83
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci U S A (2011) 2.80
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest (2008) 2.63
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy (2010) 2.62
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 2.52
Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol (2012) 2.27
A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ (2010) 2.25
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene (2009) 2.13
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13
Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res (2012) 2.12
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res (2010) 2.11
The HSP70 family and cancer. Carcinogenesis (2013) 2.06
Role and regulation of autophagy in cancer. Biochim Biophys Acta (2009) 2.00
Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One (2009) 1.91
Autophagy as a therapeutic target in cancer. Cancer Biol Ther (2011) 1.84
Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem (2008) 1.84
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res (2011) 1.84
Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A (2012) 1.82
Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis. Autophagy (2010) 1.79
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ (2011) 1.76
Autophagy and tumorigenesis. FEBS Lett (2009) 1.76
Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther (2009) 1.69
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood (2008) 1.69
Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res (2011) 1.69
AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J Cell Mol Med (2009) 1.67
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood (2012) 1.66
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med (2010) 1.65
Autophagy and disease: always two sides to a problem. J Pathol (2011) 1.64
Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer (2010) 1.63
The crosstalk between autophagy and apoptosis: where does this lead? Protein Cell (2012) 1.60
Autophagy and cancer. Exp Mol Med (2012) 1.57
Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther (2011) 1.55
Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein. Autophagy (2011) 1.47
Autophagy as a target for cancer therapy: new developments. Cancer Manag Res (2012) 1.44
Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res (2012) 1.44
Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. Oncogene (2010) 1.40
Role of autophagy in breast cancer. Autophagy (2007) 1.39
Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res (2009) 1.39
Autophagy and cancer therapy. Mol Pharmacol (2014) 1.38
Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One (2012) 1.37
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther (2014) 1.35
Targeting cancer cells through autophagy for anticancer therapy. Curr Opin Cell Biol (2010) 1.34
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood (2008) 1.31
Killing a cancer: what are the alternatives? Nat Rev Cancer (2012) 1.30
Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett (2014) 1.29
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
Autophagy and tumorigenesis. Semin Immunopathol (2010) 1.26
Emerging strategies to effectively target autophagy in cancer. Oncogene (2015) 1.26
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood (2012) 1.25
Therapeutic targeting of autophagy in disease: biology and pharmacology. Pharmacol Rev (2013) 1.25
The ARF tumor suppressor can promote the progression of some tumors. Cancer Res (2008) 1.24
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med (2011) 1.22
Autophagy modulation for cancer therapy. Cancer Biol Ther (2011) 1.20
Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux. J Cell Sci (2009) 1.20
Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem (2010) 1.20
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood (2008) 1.18
Autophagy-induced tumor dormancy in ovarian cancer. J Clin Invest (2008) 1.16
Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy (2012) 1.16
PPARgamma activation induces autophagy in breast cancer cells. Int J Biochem Cell Biol (2009) 1.14
Autophagy as a modulator and target in prostate cancer. Nat Rev Urol (2014) 1.13
Redox control of leukemia: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal (2012) 1.12
Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy (2012) 1.12
The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12
Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol (2011) 1.10
p53 and ARF: unexpected players in autophagy. Trends Cell Biol (2010) 1.08
Autophagy in tumor suppression and cancer therapy. Crit Rev Eukaryot Gene Expr (2011) 1.08
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer (2010) 1.07
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer (2012) 1.06
Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci (2012) 1.05
Autophagic pathways as new targets for cancer drug development. Acta Pharmacol Sin (2010) 1.05
Pharmacologic agents targeting autophagy. J Clin Invest (2015) 1.04
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel) (2010) 1.02
Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther (2012) 1.01
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol (2015) 1.01
Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A (2013) 1.01
Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia (2013) 1.00
Histone deacetylase inhibitors and cell death. Cell Mol Life Sci (2014) 1.00
Autophagy in blood cancers: biological role and therapeutic implications. Haematologica (2013) 0.99
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood (2014) 0.97
Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases. Radiat Oncol (2013) 0.97
Crosstalk between apoptosis and autophagy: molecular mechanisms and therapeutic strategies in cancer. J Cell Death (2013) 0.96
Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer (2011) 0.96
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res (2008) 0.94
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia (2014) 0.93
Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell (2005) 17.81
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27
DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell (2006) 9.47
Intrinsic tumour suppression. Nature (2004) 8.73
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2004) 4.20
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol (2005) 2.75
Mitochondrial defects in cancer. Mol Cancer (2002) 2.75
Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med (2003) 2.56
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res (2003) 2.30
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol (2005) 2.29
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res (2004) 2.23
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett (2005) 2.10
Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene (2003) 2.09
Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev (2005) 2.08
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene (2003) 1.96
p53 and metabolism: Inside the TIGAR. Cell (2006) 1.84
Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol (2001) 1.76
Lysosomes as targets for cancer therapy. Cancer Res (2005) 1.76
Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia (2003) 1.76
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A (2006) 1.71
The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther (2004) 1.67
Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci (2005) 1.50
Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci U S A (2004) 1.42
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood (2005) 1.34
Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res (2005) 1.32
AMN107: tightening the grip of imatinib. Cancer Cell (2005) 1.27
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia (2005) 1.21
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol (2005) 1.21
p53 downstream targets and chemosensitivity. Cell Death Differ (2003) 1.20
Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther (2003) 1.19
Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res (2005) 1.18
Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death. Mol Cancer Ther (2005) 1.14
Overexpression of both catalytically active and -inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity. Oncogene (2006) 1.13
Cellular responses to protein accumulation involve autophagy and lysosomal enzyme activation. Rejuvenation Res (2005) 1.04
Cathepsin D and H2O2 stimulate degradation of thioredoxin-1: implication for endothelial cell apoptosis. J Biol Chem (2005) 1.02
Reactive oxygen species mediate chloroquine-induced expression of chemokines by human astroglial cells. Glia (2004) 0.99
Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer. Curr Opin Investig Drugs (2001) 0.84
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov (2009) 10.32
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol (2011) 8.34
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol (2004) 7.69
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell (2003) 7.60
Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature (2007) 7.21
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell (2002) 6.05
Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med (2007) 6.01
ROS stress in cancer cells and therapeutic implications. Drug Resist Updat (2004) 5.20
NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci U S A (2007) 5.14
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
Integration with the human genome of peptide sequences obtained by high-throughput mass spectrometry. Genome Biol (2004) 4.91
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res (2005) 4.61
Human Plasma PeptideAtlas. Proteomics (2005) 4.52
Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells. Nano Lett (2007) 4.37
Redox regulation of cell survival. Antioxid Redox Signal (2008) 4.33
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2003) 4.07
Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett (2005) 3.96
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res (2008) 3.92
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res (2005) 3.79
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat Cell Biol (2006) 3.49
Myc pathways provoking cell suicide and cancer. Oncogene (2003) 3.49
Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol (2006) 3.39
A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics (2011) 3.37
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology (2007) 3.34
Automated statistical analysis of protein abundance ratios from data generated by stable-isotope dilution and tandem mass spectrometry. Anal Chem (2003) 3.33
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol (2012) 3.28
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron (2004) 3.16
c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev (2002) 3.16
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci U S A (2007) 3.12
Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol (2003) 3.04
Efficient and specific modifications of the Drosophila genome by means of an easy TALEN strategy. J Genet Genomics (2012) 2.98
PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood (2007) 2.93
CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol Cell (2002) 2.92
Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res (2006) 2.86
Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest (2008) 2.83
Toxoplasma gondii sequesters lysosomes from mammalian hosts in the vacuolar space. Cell (2006) 2.79
Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol (2010) 2.78
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 2.77
The identification of vesicular glutamate transporter 3 suggests novel modes of signaling by glutamate. Proc Natl Acad Sci U S A (2002) 2.77
Vesicular glutamate transport promotes dopamine storage and glutamate corelease in vivo. Neuron (2010) 2.75
Mitochondrial defects in cancer. Mol Cancer (2002) 2.75
Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res (2013) 2.73
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol (2006) 2.68
Navigation with electromagnetic tracking for interventional radiology procedures: a feasibility study. J Vasc Interv Radiol (2005) 2.67
TALEN-mediated precise genome modification by homologous recombination in zebrafish. Nat Methods (2013) 2.64
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol (2012) 2.59
Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature (2007) 2.52
Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest (2002) 2.50
Control of DNA replication and chromosome ploidy by geminin and cyclin A. Mol Cell Biol (2002) 2.47
Dopamine neurons mediate a fast excitatory signal via their glutamatergic synapses. J Neurosci (2004) 2.45
Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol (2006) 2.44
Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A (2006) 2.41
Mitochondrial clearance is regulated by Atg7-dependent and -independent mechanisms during reticulocyte maturation. Blood (2009) 2.39
L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage. Cell Cycle (2006) 2.37
Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. Clin Neurophysiol (2007) 2.36
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett (2008) 2.33
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer (2004) 2.31
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry (2006) 2.31
MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell (2010) 2.29
Structure-specific statistical mapping of white matter tracts. Neuroimage (2008) 2.28
Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J (2005) 2.25
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res (2006) 2.23
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res (2005) 2.22
Counting of six pRNAs of phi29 DNA-packaging motor with customized single-molecule dual-view system. EMBO J (2007) 2.21
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem (2003) 2.19
Risk factors and prevention of inguinal hernia after radical prostatectomy: a systematic review and meta-analysis. J Urol (2012) 2.17
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res (2005) 2.16
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood (2011) 2.16
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
Targeting lactate metabolism for cancer therapeutics. J Clin Invest (2013) 2.14
The anterior cruciate ligament remnant: to leave it or not? Arthroscopy (2013) 2.13
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res (2011) 2.12
Evaluating concordance to American Diabetes Association standards of care for type 2 diabetes through group visits in an uninsured or inadequately insured patient population. Diabetes Care (2003) 2.09
A software suite for the generation and comparison of peptide arrays from sets of data collected by liquid chromatography-mass spectrometry. Mol Cell Proteomics (2005) 2.08
Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A (2003) 2.07
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr (2007) 2.07
Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain (2013) 2.05
Solid-phase extraction of N-linked glycopeptides. Nat Protoc (2007) 2.05
Continuous medial representation for anatomical structures. IEEE Trans Med Imaging (2006) 2.04
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood (2004) 2.03
A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A (2006) 2.03
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci U S A (2009) 2.02
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol (2003) 1.99
The MAPK(ERK-1,2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in morphogenesis of mouse mammary epithelium. Dev Biol (2007) 1.98